Description
Palbonix (Palbociclib) indicate for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:
- An aromatase inhibitor as initial endocrine based therapy in postmenopausal women.
- Fulvestrant in women with disease progression following endocrine therapy.
Pharmacodynamics
Due to its mechanism of action, Palbociclib inhibits cell growth and suppresses DNA replication in retinoblastoma tumor suppressor gene (RB) proficient cancer cells. As expected, these RB cells present a significant increase in the proportion of cells in G1 state and the presence of Palbociclib produces effective dephosphorylation of RB, reduce proliferation and induce senescence causing cell-cycle arrest.
The potential for Palbociclib to reduce cellular proliferation of estrogen receptor-positive breast cancer cell lines through the inhibition of the cell-cycle progression from G1 to S phase. In this study, it was demonstrated that the sensitivity of the cells significantly increased with the expression of RB1 and CCND1 and low expression of CDKN2A. As well, Palbociclib, combined with antiestrogens, enhanced in vivo antitumor activity in estrogen receptor-positive breast cancer mouse models.
In clinical trials, Palbonix , in combination with letrozole, was shown to significantly increase the progression-free survival (PFS) in patients with metastatic breast cancer without prior endocrine treatment. In the results, the PFS increased from 4.5 to 9.5 months with an overall response rate (ORR) of 24.6%.
Mechanism of Action
Palbonix is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor1 that acts by binding to the ATP pocket with an IC50 in the range of 9-15 nmol/L. It is important to consider that it presents low to absent activity against other kinases.
The CDK4/6 kinase is involved, with coregulatory partner cyclin D, in the G1-S transition. Hence, inhibition of this step prevents cell cycle progression in cells in whose this pathway is functioning. This step includes the pathways of the phosphorylation of retinoblastoma protein and the E2F family of transcription factors.
Palbonix side effects
The most common side effects of Palbociclib are:
- Anemia (low red blood cell count)
- Fatigue
- Nausea
- Mouth sores
- Hair thinning or loss
- Diarrhea
- Vomiting
- Decreased appetite
Palbociclib Dosage
Palbonix 125 (Palbociclib) 125mg capsules are taken orally with food in combination with an aromatase inhibitor or fulvestrant.
- Recommended starting dose: 125 mg once daily taken with food for 21 days followed by 7 days off treatment.
- Dosing interruption and/or dose reductions are recommended based on individual safety and tolerability.
FAQ about Palbonix (Palbociclib):
Q. Is Palbonix (Palbociclib) available to supply worldwide?
Yes! We can supply Palbonix (Palbociclib) worldwide. According to WTO rules and regulations, we can supply our prescription medicine in most of the country for patient’s personal use.
Q. What’s the Palbonix (Palbociclib) minimum order quantity?
Minimum quantity order of Palbonix (Palbociclib) depends on client/ patients demand. We’ll notify it after price inquiring.
Q. What’s the Palbonix (Palbociclib) price/ cost in Russia/ USA/ UK/ India/ China/ Egypt/ other countries?
Palbonix (Palbociclib) price/ cost will be provided after getting valid order from clients/ patients. We’ll notify it after price inquiring.
Q. How I can order Palbonix (Palbociclib)?
To order this Palbonix (Palbociclib), please inquiry the price first with proper information and then add to cart.
Q. How I’ll be ensured that I’m getting the original Palbonix (Palbociclib)?
First of all, we’re licensed online pharmacy service provider. We supply most kind of generic prescription medicine globally. We’ve dealings directly with manufacturing pharma company or with their authorized agent. Therefore, here is no doubt to get original Palbonix (Palbociclib) by us. And also, you can check the security code that provided by manufacturing company whether it’s genuine or not. If you feel any issue or doubt, please inform us immediately.
For any inquiries please contact us
For more Oncology medicine, visit our SHOP
Reviews
There are no reviews yet.